True heterogeneity or post-hoc artifact?
Determine whether the subgroup is transportable, biologically coherent and capable of supporting a new claim rather than merely explaining away the miss.
Development failure & rescue benchmarks
Start with the decision pattern—not the disease label.
These public cases show how HISTAMOS separates failed claims from failed assets, identifies surviving value and defines the next discriminator. Most are independent analyses of public information, not client engagements.
01 — Commercially relevant decision patterns
The same development failure can hide very different causal worlds.
These are the patterns HISTAMOS is designed to adjudicate before the next expensive trial or agency interaction.
Target engagement or failed clinical bridge?
Separate engagement from exposure, compartment, execution, durability, function and endpoint failure.
Asset death or benefit-risk boundary?
Identify whether dose, exposure, population or remote-organ risk can be bounded without overstating the surviving benefit.
Drug failure or counterfactual failure?
Test whether the evidence architecture can support attribution before using an apparent response as proof of efficacy.
Molecule failure or decision-test failure?
Recheck whether the statistical architecture actually tests the claim the program needs to make.
Program failure or repairable evidence layer?
Separate CMC, measurement, evidence-package and execution failures from the scientific core.
02 — How public benchmarks are graded
Retrospective examples are useful—but they are not the same as a prospective call.
Structural coverage
Can the method represent a rescue route that later proved workable? Used mainly to discover blind spots.
Pre-outcome evidence only
Analysis is restricted to information available before the later regulatory or clinical outcome.
Prediction before the answer
The strongest public benchmark: the decision record is frozen before the external answer is known.
03 — Scientific research archive
The underlying scientific record remains visible—without confusing it with commercial client work.
The cases below retain their original scientific framing and next decisive tests. They support method development and public validation; no client relationship is implied unless explicitly stated.
Neogene TCR-T — resistance mechanism de-risking
Source loss, exact cognate pMHC failure, TCR-selected low-visibility escape and downstream effector failure were separated into experimentally testable worlds.
Next decisive test
Qualify exact cognate pMHC measurement, then execute a state-resolved selection, rescue, washout and fresh-TCR rechallenge experiment.
ARID1A / PPP2R1A / ATR inhibition
A broad ARID1A-response claim was narrowed to whether PPP2R1A p.R183 adds independent or interactive sensitivity and whether functional replication-stress state improves discrimination beyond genotype.
Next decisive test
Four-state factorial comparison with rescue/reversion, orthogonal ATR perturbation and locked functional-state assays.
DHA need × oxidative state
Biochemical repletion was separated from clinical benefit, while oxidative/ferroptotic vulnerability was separated from treatment-specific harm.
Next decisive test
Pre-specify deficiency and oxidative-state estimands before patient-level treatment-effect heterogeneity analysis.
Semaglutide continuation heterogeneity
The question is not whether early responders do better. It is whether a pre-specified state identifies treatment-effect heterogeneity that changes the optimal continuation policy.
Next decisive test
Randomized IPD analysis with nested cross-fitting, calibration and direct comparison to continue-all.
VMCM / SRC-SFK Functional Dependency
The broad SRC-driver interpretation was downgraded. The higher-value question is whether SRC remains a residual or parallel dependency after matched PI3K/TIE2 correction.
Next decisive test
Low-VAF molecular reclassification, endothelial-resolved signaling and SRC perturbation after matched PI3K/TIE2 correction.
Anaphylaxis — Vascular Execution Bottleneck
Single-cell observations were converted into a causal competition: immune trigger → vascular execution failure → shock versus shock → secondary vascular/pericyte damage.
Next decisive test
Temporal, cell-resolved vascular rescue after immune initiation but before full hemodynamic collapse.
Algerian IEI — Adaptive Diagnostic Architecture
The published TGP→WES strategy remained feasible, but optimality was not assumed. A function-first + WES-first + ancestry/ROH-aware interpretation with adaptive rescue was retained as the stronger prospective comparison.
Next decisive test
Equal-reference prospective comparison using time to definitive actionable diagnosis as the primary endpoint.
Fabry Disease — Isolated Microhematuria
Silent early renal involvement remained plausible, but isolated microhematuria was not promoted as an independent Fabry marker.
Next decisive test
Three-gate matched, sex-aware screening with equal reference verification and separate index-case versus family-cascade yield.
State × Exposure Boundary in Bee-Venom Toxicology
A simple pro-oxidant/antioxidant contrast was reframed as a state × exposure × cellular access × adaptive-capacity × time problem.
Next decisive test
A factorial experiment separating adaptive/protective stress from ordinary dose-dependent irreversible toxicity.
MDX2003 / ZERHOUNI-RX1M
Dual antigen coverage and conditional CD28 costimulation were retained as useful design principles, while fixed four-function integration was not credited with proven causal superiority.
Next decisive test
Matched fixed-versus-modular comparison with antigen topology, T-cell competence, cytokine window and contribution-of-components controls.
04 — Diagnostics & state
A measurable signal is not automatically a decision-grade selector.
CKD-AGE — pathology vs age-associated decline
A strong retrospective signal was retained, but equation-to-equation discrimination was not accepted as an independent pathological reference.
Next decisive test
Measured GFR subcohort, structural disease evidence, external validation and longitudinal outcomes.
Behçet immunological signature
A cross-sectional signature was kept as a signal but not promoted to prospective disease control or treatment selection.
Next decisive test
Pre-treatment locked score, serial sampling and external validation of future organ events.
Important. Most cases are independent HISTAMOS analyses of published work. Direct scientific dialogue is labeled where applicable. No institutional collaboration, endorsement or clinical recommendation is implied unless explicitly stated.
Bring one real asset decision.
A difficult readout and the next decision date are enough to request a confidential written scope.